Skip to main content
×
Login
Submit a Manuscript
Home
Journal
Current Issue
Archive
For Authors
Column Series
Research & Insight
Special Reports
Subscribe
Resources
Biosimilars Excellence Forum
Blogs
Expert Insights
Latest News
Mantle Cell Lymphoma Excellence Forum
Pathways Beyond Oncology
Topics
Comparative Effectiveness Research
Cost-Effectiveness Research
COVID-19 Updates
Guideline Updates
Health Economics and Outcomes Research
Health Technology
Real-World Data
Reimbursement
Value-Based Care
Specialties
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
B-Cell Lymphoma
Biosimilars
Bladder Cancer
Breast Cancer
CAR-T Therapies
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Colorectal Cancer
Diffuse Large B-Cell Lymphoma
Follicular Lymphoma
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Head and Neck Cancer
Immuno-Oncology
Kidney Cancer
Liver Cancer
Lung Cancer
Mantle Cell Lymphoma
Melanoma
Multiple Myeloma
Non-Small Cell Lung Cancer
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Skin Cancer
Supportive Care
Conferences
Oncology Clinical Pathways Congress
ASCO Gastrointestinal Cancers Symposium
ASCO Genitourinary Cancers Symposium
ASH Annual Meeting and Exposition
Oncology CME
About
About Us
Contact
Mantle Cell Lymphoma
Featured
Quiz
Quiz: Is Pre-Transplant MRD Status Predictive of Survival in MCL?
True of False: MRD status prior to autologous stem cell transplantation is an early predictor of PFS and OS in younger patients with MCL.
News
Real-World Practice Patterns, Comorbidities in Medicare Patients With MCL
Older patients with MCL have a high rate of comorbidities impacting treatment choices and OS.
News
MRD Linked to Worse Survival Outcomes in Patients With MCL
Positive MRD status after induction and consolidation treatments for patients with MCL is associated with worse PFS and…
Conference Coverage
Pre-Transplant MRD Status Predicts PFS, OS in Patients With MCL
MRD status in peripheral blood or bone marrow prior to autoSCT is an early predictor of PFS and OS in younger patients…
Special Reports
Product Perspectives: Brukinsa (Zanubrutinib) for Mantle Cell Lymphoma (Sponsored)
An interview with David Andorsky, MD, Rocky Mountain Cancer Centers, Boulder, Colorado.
News
Real-World Practice Patterns, Comorbidities in Medicare Patients With MCL
MRD Linked to Worse Survival Outcomes in Patients With MCL
Treatment Patterns and Outcomes Among US Patients With MCL Treated With Ibrutinib
Significant Economic and Health-Related QoL Burden Associated With MCL
Podcast
Novel BTK Inhibitor Promising for Mantle Cell Lymphoma
Conference Coverage
Clinical and Economic Burden of MCL in the VHA Population
Stay in the know.
Journal of Clinical Pathways Newsletter
Back to Top